An open-label, non-randomized study to evaluate the efficacy and safety of BAY94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detection/exclusion of cerebral beta-amyloid when compared to postmortem histopathology

Trial Profile

An open-label, non-randomized study to evaluate the efficacy and safety of BAY94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detection/exclusion of cerebral beta-amyloid when compared to postmortem histopathology

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2016

At a glance

  • Drugs Florbetaben F18 (Primary)
  • Indications Alzheimer's disease
  • Focus Diagnostic use; Registrational
  • Sponsors Piramal Imaging
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 31 Aug 2015 According to a Piramal Imaging media release, data from this study were published in the current issue of Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
    • 08 Jun 2015 According to Piramal Imaging media release, results were presented at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top